关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 公告文件 证券代码：000989 证券简称： 九芝堂 公告编号：2024-001 九芝堂股份有限公司 九芝堂股份有限公司（以下简称"公司"）近日接到公司控股股东李振国先 生函告，获悉其所持公司部分股份被质押，具体事项如下： 上述质押股份未负担重大资产重组等业绩补偿义务。 二、股东股份累计质押基本情况 | | | | | 合计占 | 合计占 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 持股数量 | 持股比 | 累计被质押 | 其所持 | 公司总 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | 称 | | 例 | 数量 | 股份比 | 股本比 | 限售合计数 | 押股份 | 限售合计数 | 押股份 | | | | | | 例 | 例 | 量 | 比例 | 量 | 比例 | | 李振国 | 215,398,371 | 25.1 ...

关于公司董事会、监事会延期换届选举的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导 性陈述或者重大遗漏负连带责任。 公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2023-061 九芝堂股份有限公司 九芝堂股份有限公司董事会 2023 年 12 月 23 日 九芝堂股份有限公司 1 九芝堂股份有限公司（以下简称"公司"）第八届董事会、监事会任期将于 2023 年 12 月 28 日届满，鉴于公司新一届董事会、监事会换届工作尚在筹备推 进中，为确保相关工作的连续性及稳定性，公司董事会、监事会的换届选举将适 当延期，董事会各专门委员会及高级管理人员的任期也相应顺延。在公司新一届 董事会、监事会换届选举工作完成前，公司第八届董事会、监事会、董事会各专 门委员会成员及高级管理人员将按照相关法律法规和《公司章程》等有关规定， 继续履行董事、监事及高级管理人员的职责和义务。 公司董事会、监事会延期换届不会对公司正常运营产生影响。公司将积极推 进董事会、监事会换届选举工作进程，并严格按照相关法律法规的规定履行换届 选举的决策程序，及时履行信息披露义务。 特此公告。 ...

临时公告 三、对公司的影响 证券代码：000989 证券简称：九芝堂 公告编号：2023-059 九芝堂股份有限公司 关于主要产品疏血通注射液在 2023 年国家医保目录中 解除部分限制的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导 性陈述或者重大遗漏负连带责任。 2023 年 12 月 13 日，国家医保局、人力资源社会保障部发布《关于印发<国 家基本医疗保险、工伤保险和生育保险药品目录（2023 年）>的通知》（医保发 〔2023〕30 号）（以下简称"《2023 年医保目录》"）。在《2023 年医保目录》 中，九芝堂股份有限公司（以下简称"公司"）全资子公司牡丹江友搏药业有限 责任公司（以下简称"友搏药业"）主要产品疏血通注射液的备注限制内容有部 分调整，解除了部分限制，现将有关情况公告如下： 二、疏血通注射液销售情况 | 药品名称 | 2023年前三季度疏血通注射液 | 2023年前三季度疏血通注射液营业 | | --- | --- | --- | | | 营业收入（万元） | 收入占公司营业收入的比例 | | 疏血通注射液 | 48806.68 | 20.59 ...

临时公告 证券代码：000989 证券简称：九芝堂 公告编号：2023-058 九芝堂股份有限公司 关于全资子公司研发新药启动临床试验的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导 性陈述或者重大遗漏负连带责任。 2023 年 12 月 13 日，九芝堂股份有限公司(以下简称"公司"或"本公司") 全资子公司牡丹江友搏药业有限责任公司(以下简称"友搏药业")与复旦大学 附属华山医院、康龙化成（成都）临床研究服务有限公司（临床 CRO 公司）召开 了关于开展"评价中国健康成人受试者单次和多次静脉注射 YB211 的耐受性、安 全性和药代动力学特征的单中心、随机、盲法、对照设计的 I 期临床试验"的临 床试验启动会。现将主要相关情况公告如下： 一、临床试验项目基本情况 1、YB211项目是具有全新化学结构的环脂肽类1类化药新药，其化合物、制 备方法等核心技术均已获得国际和国内发明专利授权与全球独家许可。本药品申 请适应症为对本品敏感的革兰氏阳性病原菌所致的复杂性皮肤及软组织感染 （cSSTI），其研发旨在提高环脂肽类抗菌药物的安全性与有效性，为临床提供 一种新的选择。 2、本 ...

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2023-060 九芝堂股份有限公司 关于持股 5%以上股东减持计划期限届满暨实施结果的公告 股东黑龙江辰能工大创业投资有限公司保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 九芝堂股份有限公司（以下简称 "公司"）于 2023 年 5 月 20 日披露了《关 于持股 5%以上股东减持股份预披露公告》（公告编号：2023-038），公司股东 黑龙江辰能工大创业投资有限公司（以下简称"辰能创投"）计划在减持计划公 告之日起 15 个交易日后的 6 个月内以集中竞价交易或大宗交易方式减持本公司 股份不超过 17,118,840 股（占本公司总股本比例 2%）。 公司于 2023 年 12 月 12 日收到辰能创投出具的《关于所持九芝堂股份减持 计划实施进展暨减持完毕的告知函》，截至 2023 年 12 月 11 日，辰能创投的上 述减持计划期限已届满并已实施完毕，相关详细情况如下： 一、股份减持实施情况 1、截至 2023 年 12 月 11 日，辰能创投减 ...

Group 1: Event Details - The event is titled "2023 Hunan Listed Companies Investor Online Collective Reception Day" [2] - It will be held on November 2, 2023, from 15:30 to 17:00 [2] - Investors can participate via the "Panjing Roadshow" website, WeChat public account, or the Panjing Roadshow APP [2] Group 2: Company Commitment - The company and its board guarantee the authenticity, accuracy, and completeness of the announcement [2] - They accept joint liability for any false records, misleading statements, or significant omissions [2] Group 3: Interaction Focus - Company executives will communicate with investors regarding development strategies and operational status [2] - The event aims to enhance interaction and communication with investors [2]

Financial Performance - The company's operating revenue for the current reporting period is ¥551,322,356.98, a decrease of 3.99% compared to the same period last year[13]. - Net profit attributable to shareholders for the current reporting period is ¥43,908,213.25, an increase of 91.92% year-on-year[13]. - Net profit attributable to shareholders after deducting non-recurring gains and losses is ¥34,247,726.32, up 97.93% compared to the same period last year[13]. - The net profit for the third quarter is 287,515,147.59 yuan, a decrease from 388,794,815.90 yuan in the same period last year, representing a decline of approximately 26%[29]. - The total profit for the quarter is 346,940,382.42 yuan, down from 503,003,968.20 yuan year-on-year, indicating a decrease of about 31%[29]. - The company’s operating profit for the quarter is 346,347,507.16 yuan, down from 500,149,564.49 yuan year-on-year, reflecting a decrease of approximately 31%[29]. - The total comprehensive income attributable to the parent company for the current period is CNY 302,296,687.66, compared to CNY 373,677,043.63 in the previous period, reflecting a decrease of approximately 19.1%[32]. - Basic and diluted earnings per share for the current period are both CNY 0.3373, down from CNY 0.4572 in the previous period, indicating a decline of about 26.2%[32]. Assets and Liabilities - Total assets increased to ¥5,398,434,079.72 from ¥5,239,728,801.58, representing a growth of approximately 3.03%[1]. - Current liabilities rose to ¥1,366,623,705.14 from ¥1,159,506,104.85, an increase of about 17.88%[1]. - Non-current liabilities decreased to ¥91,070,406.22 from ¥98,955,228.70, a decline of approximately 8.93%[1]. - Total liabilities increased to ¥1,457,694,111.36 from ¥1,258,461,333.55, a rise of about 15.83%[1]. - Total equity attributable to shareholders decreased to ¥3,945,310,836.44 from ¥3,984,827,136.94, a reduction of about 1.00%[5]. - The total current assets increased to ¥2,972,101,611.61 from ¥2,797,935,355.28, reflecting a growth of about 6.19%[6]. Cash Flow - The net cash flow from operating activities decreased by 87.94% year-on-year, amounting to ¥45,668,461.80[13]. - The net cash flow from operating activities for the current period is CNY 45,668,461.80, compared to CNY 378,827,633.83 in the previous period, indicating a significant decline[33]. - The net cash flow from investing activities for the current period is -CNY 612,418,606.77, slightly worse than -CNY 598,740,917.76 in the previous period[35]. - The net cash flow from financing activities for the current period is -CNY 128,660,899.54, compared to -CNY 361,063,945.95 in the previous period, showing an improvement[35]. - The total cash and cash equivalents at the end of the period is CNY 393,934,400.07, down from CNY 227,103,425.45 in the previous period[35]. - Cash and cash equivalents decreased to ¥393,934,400.07 from ¥1,089,345,444.58, a decline of approximately 63.8%[6]. Accounts Receivable and Inventory - Accounts receivable increased to ¥649,308,222.42 from ¥291,350,016.43, representing a growth of about 123.5%[6]. - Inventory increased to ¥788,287,399.63 from ¥749,171,033.03, an increase of approximately 5.2%[6]. - The company reported a significant increase in accounts receivable by 122.86%, reaching ¥64,930.82 million[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 53,717, with the top 10 shareholders holding a combined 56.05% of shares[21]. - Li Zhenguo holds 25.17% of shares, while Heilongjiang Cheneng Gongda Venture Capital Co., Ltd. holds 18.79%[21]. - The report indicates that there are no related party relationships among the top 10 shareholders, and they are not acting in concert[21]. Research and Development - The company’s subsidiary, Mudanjiang Youbo Pharmaceutical Co., Ltd., received approval for clinical trials of a new drug, YB211, from the National Medical Products Administration[24]. - Research and development expenses increased slightly to CNY 91,241,164.16 from CNY 88,935,071.45, reflecting a growth of about 2.5%[36]. Operating Costs - Total operating costs for the current period are CNY 2,066,143,905.54, down from CNY 2,217,629,799.25, representing a reduction of about 6.8%[36]. - The company reported a decrease in sales expenses to CNY 869,241,636.60 from CNY 888,599,556.72, a reduction of approximately 2.9%[36].

证券代码：000989 证券简称：九芝堂 | --- | --- | --- | |------------|---------------------------|-------------| | | □特定对象调研 √分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系 | | | | | □新闻发布会 □路演活动 | | | 活动类别 | | | □现场参观 □其他 （请文字说明其他活动内容） 2023 年 8 月 8 日：开源证券、华安证券、天风证券、东北证券、 参与单位名 兴业证券、西部证券、华创证券、申万宏源证券、华泰证券、国 称、人员姓 盛证券、国海证券、平安证券、国金证券、安信证券医药行业分 名、时间 析师以及多家机构投资者投资经理、分析师、研究员等 地点 电话会议 上市公司接 待人员姓名 财务总监张梁彬、董事会秘书韩辰骁 Q1：介绍公司半年度经营情况： 2023 年上半年公司实现营业收入 18.19 亿元，比上年同期下 降 3.72%，同比下降的原因主要是去年公司完成九芝堂医药 51% 股权转让后不再将其纳入公司合并报表范围，上年同期纳入合并 报表范围的九芝堂医药营业 ...

Shareholder Meetings - The company held its first extraordinary general meeting of shareholders in 2023 with a participation ratio of 46.46% on January 10, 2023[2]. - The annual general meeting of shareholders in 2022 had a participation ratio of 55.44% on May 24, 2023[2]. Environmental Compliance - The company has implemented strict environmental monitoring and published all self-monitoring data as required in the first half of 2023[6]. - The company emphasizes environmental protection and has achieved compliance with national standards for waste disposal, wastewater treatment, and emissions control[8]. - The company has implemented measures to reduce carbon emissions, although specific results were not disclosed[7]. - The company has maintained stable pollutant discharge levels across its three production sites, with total emissions below the approved limits[100]. - The company has plans for future expansion and investment in wastewater treatment technologies to enhance compliance and sustainability[135]. - The company is actively monitoring and managing wastewater discharge to ensure compliance with environmental regulations[135]. - The company has established emergency response plans for environmental incidents, with registrations completed in 2021 and 2022[137]. - The company has maintained compliance with environmental discharge standards, with specific pollutant levels reported[112][115]. Corporate Governance - The company has established a robust corporate governance system to protect creditor rights and ensure financial stability[8]. - The company reported a commitment to avoid competition with its controlling shareholder, Li Zhenguo, ensuring no direct or indirect involvement in competing businesses during his tenure as a controlling shareholder[28]. - Li Zhenguo and associated parties committed to reducing and regulating related party transactions to protect the company's interests, ensuring fair and lawful agreements are made if necessary[28]. - The company confirmed that there were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[32]. - The company has maintained its independence in operations, finance, and governance, ensuring no interference from controlling shareholders[28]. - There were no significant litigation or arbitration matters affecting the company during the reporting period[38]. - The company has not engaged in any violations regarding external guarantees during the reporting period[33]. - There were no significant related party transactions reported, ensuring transparency and compliance with regulations[40]. - The company has not undergone any bankruptcy restructuring during the reporting period, indicating financial stability[37]. - The company has maintained a clean integrity status with no unfulfilled court judgments or significant debts due during the reporting period[39]. Financial Performance - The company's operating revenue for the reporting period was ¥1,818,909,467.04, a decrease of 3.72% compared to ¥1,889,171,555.86 in the same period last year[55]. - The net profit attributable to shareholders was ¥244,827,549.04, down 33.55% from ¥368,443,161.49 in the previous year, primarily due to investment income from the 51% equity transfer of Jiuzhitang Pharmaceutical in the previous year[55]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 77.40% to ¥236,067,910.38, driven by increased product sales and improved gross margin[55]. - The net cash flow from operating activities decreased by 50.73% to ¥138,156,212.78, mainly due to an increase in accounts receivable and the exclusion of Jiuzhitang Pharmaceutical from the consolidated financial statements[55]. - Total assets at the end of the reporting period were ¥5,488,411,303.99, an increase of 4.77% from ¥5,238,415,577.39 at the end of the previous year[55]. - The company's weighted average return on equity was 6.04%, down 2.83% from 8.87% in the previous year[55]. - The company reported a total of ¥1,048,414,502.00 in undistributed profits, down from ¥1,145,963,757.76, a decrease of about 8.5%[185]. - Total operating revenue for the first half of 2023 was CNY 1,818,909,467.04, a decrease of 3.8% compared to CNY 1,889,171,555.86 in the same period of 2022[194]. - Total operating costs decreased to CNY 1,543,377,122.69 from CNY 1,684,136,256.53, reflecting a reduction of approximately 8.4%[194]. - Net profit for the first half of 2023 was CNY 243,903,752.14, down 33.5% from CNY 366,909,887.08 in the first half of 2022[197]. - Earnings per share (EPS) for the first half of 2023 was CNY 0.28603, compared to CNY 0.43045 in the same period of 2022, indicating a decline of 33.5%[197]. - The company's total liabilities increased to CNY 1,662,466,711.12 from CNY 1,367,891,283.27, representing a growth of approximately 21.5%[194]. - Total equity rose to CNY 9,146,012,886.47 from CNY 9,067,837,165.09, an increase of about 0.9%[194]. - Research and development expenses for the first half of 2023 were CNY 60,904,100.05, up from CNY 51,465,136.34, reflecting a growth of approximately 18.9%[194]. Product Development and Market Position - The company is positioned to benefit from the growing demand for traditional Chinese medicine, particularly in the context of an aging population and increasing chronic disease prevalence[66]. - The State Administration for Market Regulation has introduced new regulations to strengthen the management of traditional Chinese medicine, which is expected to create new opportunities for research and development in this area[67]. - The company anticipates that the implementation of the "14th Five-Year Plan" will enhance the development of traditional Chinese medicine services and innovation capabilities[67]. - The pharmaceutical industry is facing challenges such as price pressures and increased competition, but it is also expected to achieve high-quality development driven by innovation and policy support[66]. - The company has developed a series of blood-nourishing products centered around donkey-hide gelatin, with the "Donkey-hide Gelatin Blood Nourishing Granules" ranking among the top in the national retail market for blood-nourishing products[71]. - The company has a total of 211 products included in the 2022 National Medical Insurance Catalog, with 137 in Category A and 74 in Category B, including 9 exclusive varieties[88]. - The company has established a modern large-scale pharmaceutical enterprise with 19 subsidiaries, integrating research, production, sales, and health management[68]. - The company has 327 national drug registration approvals, including 35 exclusive varieties, covering various fields such as cardiovascular, kidney tonics, and women's and children's health[88]. - The company has developed innovative businesses in stem cells and health services, expanding its product offerings beyond traditional Chinese medicine[68]. - The company has a strong brand advantage and product reputation in the OTC traditional specialty products across various medical fields[71]. - The company achieved steady growth in sales of its main products, including Shu Xue Tong injection, with significant performance improvements in the first half of 2023 compared to the same period last year[149]. - The company is advancing multiple projects, including re-evaluation of existing products and innovation in drug development, with key products undergoing pharmacological and clinical effectiveness studies[150]. - The YB209 project has officially started clinical trials, and the YB211 project has received formal acceptance for clinical trial application from the National Medical Products Administration[150]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 51,855, with a total shareholding of 215,398,371 shares, representing 25.17%[145]. - The company’s management has locked shares, with a total of 197,951,459 limited sale shares at the beginning of the period, and 31,883,925 shares released during the period[143]. - The company’s stockholder, Li Zhenguo, holds 25.17% of the shares, with 165,711,278 shares under limited sale conditions[145]. - The company reported a decrease in limited sale shares from 197,951,459 (23.13%) to 166,067,534 (19.40%) after a reduction of 31,883,925 shares[140]. - The total number of shares increased from 855,942,012 to 855,942,012, with no change in total shares[140]. - The company has not reported any changes in the status of pledged, marked, or frozen shares[145]. Operational Efficiency - The company has optimized its management structure to enhance operational efficiency and has implemented a budget management system to improve service efficiency[155]. - The company is committed to optimizing its organizational structure and enhancing production efficiency to strengthen its core competitiveness[98]. - The procurement strategy includes competitive bidding and direct sourcing to reduce costs and manage supply effectively[91]. - The sales model combines self-operated and agency sales, expanding both traditional and online sales channels[92]. - The company has implemented a production model that emphasizes quality, safety, and environmental protection, adhering to national GMP standards[90]. Awards and Recognition - The company has received multiple awards, including being ranked among the "Top 100 Chinese Traditional Medicine Enterprises" and recognized for its high-quality development in the pharmaceutical industry[157]. - The company reported a brand value of 10.803 billion RMB, ranking in the top 10 of the "Chinese Time-honored Brand Value List" with a brand strength score of 871[159]. - The company received multiple awards for quality and brand recognition, including being named a "Leading Brand in the Pharmaceutical Industry" by the China Quality Inspection Association[158].

证券代码：000989 证券简称：九芝堂 九芝堂股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |----------------|---------------------------|----------------------------|--------------------------------------| | | | | 编号：20230531005 | | | √特定对象调研 □分析师会议 | | | | | □媒体采访 □业绩说明会 | | | | 投资者关系活 | | | | | | □新闻发布会 □路演活动 | | | | 动类别 | | | | | | □现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参 与 单 位 名 | 2023 年 5 月 31 日： | | 民生证券、大成基金、上海证券、前海开 | | 称、人员姓名、 | | | | 时间金等单位的分析师、投资经理等 地点 九芝堂股份有限公司（长沙基地） 上市公司接待 人员姓名 董事会秘书韩辰骁 一、公司安排调研人员参观公司企业文化展厅、公司浓缩丸生 ...